Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Instagram Outage Disrupts Thousands of U.S. Users 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
BOULDER, Colo., June 12, 2017 -- UMF Group Inc. (OTC Pink:UMFG) (“the Company”) is pleased to announce that internal testing and research is being conducted in preparation for patent applications. UMF Group Inc. is an innovative Medical Marijuana company, which aims to develop and approve particular extracts as pharmaceuticals. The company is conducting data analysis for the proprietary “whole plant” method of extracting various cannabinoids from the marijuana plant and converting them into higher quality and quantity.
The patent application relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
Recently, public interest in Cannabis as medicine has been growing, based in no small part on the fact that Cannabis has long been considered to have medicinal properties, ranging from treatment of cramps, migraines, convulsions, appetite stimulation and attenuation of nausea and vomiting. In fact, a report issued by the National Academy of Sciences' Institute of Medicine indicated that the active components of Cannabis appear to be useful in treating pain, nausea, muscle spasms in multiple sclerosis as well as other problems.
The global demand is growing exponentially and the increasing interest amongst the academic researchers and healthcare providers regarding the therapeutic uses of marijuana is among the significant factors driving the international market over the coming years. A 2017 report from Grand View Research, Inc. estimates that the global medical marijuana market will reach a value of $55.8 billion by 2025.
FORWARD LOOKING STATEMENT
This news release includes forward-looking statements that reflect UMF Group Inc. current expectations about its future results, performance, prospects and opportunities UMF Group Inc. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to UMF Group Inc. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2017 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.
Contact: Sean Ross, President UMF Group Inc. [email protected]
